Two new studies presented at the American Academy of Neurology meeting found that ARICEPT treatment improved cognition in patients with mild cognitive impairment (MCI) and reduced behavioral symptoms in those with Parkinson's-related dementia. These findings provide encouraging news for millions of Americans affected by MCI.
A study showed that ARICEPT, a leading Alzheimer's treatment, is also effective in treating vascular dementia (VaD). Patients with VaD who received ARICEPT demonstrated significant improvements in cognition and daily living activities. The study suggests that ARICEPT may be an important measure of treatment success for VaD patients.
A new analysis of the Moderate to Severe Alzheimer's Disease Study (MSAD) found that ARICEPT significantly improved global function, cognition, and activities of daily living in patients with severe Alzheimer's disease. The study showed that ARICEPT also reduced behavioral symptoms associated with the disease.